Combination Regimen Prolongs PFS in Recurrent Ovarian Cancer but Decreases Quality of Life
May 17th 2010
According to a study presented at the Society of Gynecologic Oncology 41st Annual Meeting on Women's Cancer, held in San Francisco,
California, a combination of docetaxel(Taxotere) and carboplatin almost doubled progression-free survival (PFS) in patients with
recurrent, platinum-sensitive ovarian cancer.